3 May 2018 - PHARMAC is pleased to announce the approval of an agreement with Bayer New Zealand Limited for the listing of aflibercept and rivaroxaban in Section B (Community) and in Part II of Section H (Hospital) of the Pharmaceutical Schedule.

The above changes were the subject of the consultation letter dated 27 March 2018.

In summary, this decision will:

• list aflibercept (Eylea) inj 40 mg per ml, 0.1 ml vials in Section B and in Part II of Section H of the Pharmaceutical Schedule, with restrictions, from 1 June 2018;
  
• amend ranibizumab restrictions from 1 June 2018;
  
• list rivaroxaban (Xarelto) 10 mg in a 30 tablet pack size, and rivaroxaban 15 mg and 20 mg tablets in a 28 tablet pack size in Section B and in Part II of Section H of the Pharmaceutical Schedule, without indication restrictions, from 1 August 2018;
  
• remove the restrictions and reduce the price and subsidy of rivaroxaban (Xarelto) 10 mg tablets in the 15 tablet pack size from 1 August 2018.
  

Read PHARMAC press release